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Summary
 Giant cell glioblastoma is an infrequent variety 
of glioblastoma (5% of the cases). It has deserved 
a separate category in the World Health Organiza-
tion classification of grade IV tumors. The clinical, 
imaging, histological and immunohistochemical cha-
racteristics, and the genetic alterations are reviewed. 
Treatment and prognosis are discussed and updated. 
The case of a patient that survived 19 months and 
died of spinal leptomeningeal metastases is illustra-
ted.
KEYWORDS: Giant cell glioblastoma. Leptomeningeal 
metastases. Surgery. Temozolomide. Radiotherapy. 
Glioblastoma de células gigantes: revisión de la litera-
tura e ilustración de un caso
Resumen
 El glioblastoma de células gigantes es una 
variante rara dentro de los glioblastomas (5% de 
los casos). En la clasificación de la Organización 
Mundial de la Salud esta entidad ha merecido una 
categoría aparte en los tumores de grado IV. Se 
revisan las características clínicas, radiológicas, 
histológicas, inmunohistoquímicas y las alteraciones 
genéticas que caracterizan este tumor. El tratamiento 
y el pronóstico son discutidos aportando información 
actualizada. Finalmente se presenta un caso clínico 
ilustrado, en el cual el paciente sobrevivió durante 19 
meses, falleciendo como consecuencia de una disemi-
nación espinal leptomeníngea.
PALABRAS CLAVE: Glioblastoma de células gigantes. 
Metástasis leptomeníngeas. Cirugía. Temozolomida. 
Radioterapia
Introduction
 Unlike the “common” glioblastoma, giant cell glio-
blastoma is not encountered in everyday practice and it 
probably comes as an unexpected diagnosis most of the 
times. Despite certain similarities between the two disease 
processes, there are differences that may be of relevance 
for the management of the occasional patient harboring this 
lesion. A case of giant cell glioblastoma managed at the 
authors’ institution is reported and the key features of giant 
cell glioblastoma are reviewed.
Clinical case 
 A 54 year-old man presented with headache and motor 
dysphasia of short duration. MR disclosed a voluminous 
mass in the left temporal lobe (figure 1-A&B). The patient 
was operated. A frontotemporal approach was employed. 
The lesion had a good cleavage plane, was moderately 
hemorrhagic and was totally resected in a piece meal 
fashion. The postoperative course was uneventful. Histo-
logical examination disclosed a highly cellular neoplasm 
with marked pleomorphism. Prominent giant cells and 
numerous atypical mitotic figures were found (figure 1-C). 
Reticulin was abundant in the stroma. Immunohistoche-
mistry showed positivity for GFAP, S100 protein and p53. 
The picture was consistent with giant cell glioblastoma. 
Adjuvant radiotherapy (60Gy) and chemotherapy (temo-
zolomide) were given. There was no evidence of relapse at 
the 14 month follow up MR (figure 1-D). The patient was 
symptom free and had no neurological deficits at that time. 
Three months after, the patient complained of backache, 
lower limb weakness and deteriorating general condition. 
MR disclosed spinal leptomeningeal metastases (figure 1-
E). Curiously there was no evidence of relapse at the origi-
nal site. No further treatments were employed. The patient 
died 19 months after surgery.
Comments
 “Common” glioblastoma is a diagnosis that implies 
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Figure 1. A: preoperative axial T2 weighted MR image; a quite homogeneous subcortical mass in the left temporal lobe with 
well defined borders and associated  edema. B: preoperative coronal T1 weighted MR image; marked contrast enhancement 
is seen. C: H&E stained slide high power view; a characteristic giant cell is present in the center of the field. D: postopera-
tive coronal T1 weighted MR image 14 months after surgery; no mass and no contrast enhancement. E: postoperative sagital 
T1 weighted MR image 17 months after surgery; spinal leptomeningeal metastases.
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most of the times a very short survival. Despite this being a 
case of giant cell glioblastoma, in the beginning it was not 
felt that its course would be very different. However, the 
patient responded very well to surgery and adjuvant treat-
ments and the situation started to be regarded with some 
enthusiasm and optimism. Nevertheless, relapse occurred 
and it came in a somewhat unexpected fashion.
Review of the literature
 Giant cell glioblastoma has merited a separate category 
in the World Health Organization (WHO) classification of 
tumors as a grade IV tumor of astrocytic origin36. Micros-
copically, giant cells with nuclei of variable number, size 
and shape are the characteristic feature. These cells may 
reach up to 500 μm. Cells of small dimension are seen as 
well. The lesion is highly cellular. In certain cases abundant 
stromal reticulin fibers can be found. Prominent nucleoli, 
typical and atypical mitotic figures, and irregularly shaped 
chromatin fragments are encountered. Necrosis is present, 
namely in pseudo-palisading or large ischemic forms. The 
accumulation of tumor cells around blood vessels may ori-
ginate pseudo-rosette formation. An in vitro study showed 
that some giant multinucleated cells might have originated 
from the conversion of a number of small tumor cells, also 
of astrocytic origin20. Giant tumor cells may show lipid 
accumulation27,41, and abundant microcalcifications may be 
present as well27. Infiltration of the tumor by cells pertaining 
to the immune system can be prominent, namely mononu-
clear leukocytes44 and eosinophilic granulocytes35. Cellular 
whorls can also be a feature of the tumor23. Cytology may 
give a clear, even diagnostic, impression of the tumor at the 
time of surgery16. A mixed ganglion cell tumor - giant cell 
glioblastoma morphology has been described10, as well as 
the presence of an oligodendroglial component26.
 The correct origin and classification of the tumor has 
been determined by immunohistochemistry profiles. Glial 
fibrillary acidic protein (GFAP) positivity supports the 
glial origin of the lesion, and thereby turns inadequate the 
previously used designation “monstrocellular sarcoma”33. 
Immunohistochemistry studies show staining of tumor 
cells for GFAP21,22, vimentin21,22 S-100 protein21, and alpha-
1 anti-chymotrypsin22. GFAP staining is equally intense 
over perikaryons and processes43,48. There may be a focal 
dissociation of immunoreactivity for GFAP and S-100 pro-
tein24.
 An important differential histological diagnosis of giant 
cell glioblastoma is pleomorphic xanthoastrocytoma. They 
have in common the presence of giant tumor cells, infil-
tration of lymphocytes, deposition of reticulin and gross 
circumscription31. It has been hypothesized that in young 
girls giant cell glioblastoma may derive from pleomorphic 
xanthoastrocytoma21. The question of a possible progres-
sion of anaplastic pleomorphic xanthoastrocytoma (WHO 
grade III) from pleomorphic xanthoastrocytoma (WHO 
grade II) towards giant-cell glioblastoma (WHO grade IV) 
has been raised49. Clinical and histological criteria that aid 
in the differentiation between giant cell glioblastoma and 
pleomorphic xanthoastrocytoma have been summarized; 
quicker evolution of seizures, numerous great sized giant 
cells, numerous mitoses, atypical mitoses and necrosis 
with pseudo-palisading will favor giant cell glioblastoma11. 
Different immunohistochemical profiles for neuronal anti-
gens (class III beta-tubulin, neuronal nuclear antigen, neu-
rofilament protein, synaptophysin, GFAP) and p53 allow 
for the differentiation between giant cell glioblastoma 
and pleomorphic xanthoastrocytoma. GFAP and class III 
beta-tubulin are positive in both tumors. Positivity for p53 
is seen in giant cell glioblastoma but not in pleomorphic 
xanthoastrocytoma. Negativity for neuronal nuclear anti-
gen, neurofilament protein and synaptophysin is seen in 
giant cell glioblastoma but not in pleomorphic xanthoas-
trocytoma31. A more difficult differential is with anaplastic 
pleomorphic xanthoastrocytoma; in the latter the labeling 
index will not rise beyond 14%; mitoses, although possibly 
more than 5/10 high power fields will not reach a number 
as high as that of a giant cell glioblastoma (15-20/10 high 
power fields); slower clinical course and lack of great sized 
giant cell are also expected11.
 Giant cell glioblastoma represents 0.8% of brain 
tumors and 5% of glioblastomas in general37. Giant cell 
glioblastoma predominates in the cerebral hemispheres, 
mainly subcortically in the temporal and parietal lobes36. 
Other possible primary locations include the cerebe-
llum14,22,41 the lateral ventricles3, the optic chiasm7 and the 
spinal cord17. The lesion can be multifocal38. Spinal lepto-
meningeal metastases9, and extraneural metastases46 have 
been reported. The duration of symptoms is usually short, 
and the clinical presentation is similar to that of “common” 
glioblastoma36. On occasion it may be somewhat atypical 
such as intracerebral hemorrhage in the context of traffic 
accident8, or cranial-spinal subarachnoid hemorrhage9. 
The mean age at presentation has been calculated to be 42 
years and a male predominance described (M/F ratio 1.6); 
35% occur in people under 40 years36. Possible associated 
disorders of genetic origin include neurofibromatosis type 
127 and tuberous sclerosis2. In the sequence of the study 
of central nervous system tumors induced in primates, an 
association of human giant cell glioblastoma with JC virus 
or progressive multifocal leukoencephalopathy has been 
hypothesized32.
 Recently, the total number of published cases in the 
“pediatric age group” has been estimated to be 53 since 
1952, and in a large series of pediatric brain tumors, giant 
cell glioblastoma constituted 1/364 (0.2%)11. Cases in 
patients aged less than 10 years old have been estimated 
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to constitute 6%, and those in patients between 10 and less 
than 20 years 9% of the total36. One case has been reported 
in a child only 1-year-old2.
 From the imaging perspective giant cell glioblastoma 
has been described as a well demarcated lesion, but no 
distinguishing features were found when compared to the 
“common” glioblastoma1. However, the lesion can evolve 
from well circumscribed and homogeneous, to infiltrative 
and heterogeneous in a four month period8. Magnetic reso-
nance (MR) may disclose a contrast enhancing heteroge-
neous mass, with solid and cystic areas, hypointense on T1 
weighted sequences, hyperintense on T2 weighted sequen-
ces, surrounded by edema14. The cyst with mural nodule 
appearance has been described as well9. The value of MR 
spectroscopy, diffusion weighted imaging and perfusion 
imaging in addition to routine MR imaging have been 
emphasized; these techniques may offer clues that allow 
for a better differential diagnosis between glioblastomas, 
the giant cell variety included, and other pathologies14. 
 The treatment strategy has generally included surgery 
which by itself may offer 32 weeks of mean survival time37; 
one anecdotic patient treated with surgery alone survived 
for 17 years and 9 months and died of an unrelated cause44. 
Intraoperatively the tumor has been described as friable, 
moderately vascularized, amenable to suction, partially 
cystic and with a good cleavage plane3; another report 
describes it as solid, firm and well demarcated44; adhesion 
to the dura can occur51. The benefit of adjuvant treatment 
with radiotherapy has been established, adding 25 weeks 
to the total mean survival time37. Use of chemotherapy has 
been described as well, although protocols are quite varia-
ble26,47,51.
 Anecdotic cases of extremely long survival ranging 
from 11 to 17 years without evidence of recurrence have 
been reported26,27,44,51. In a case of recurrence of giant cell 
glioblastoma nine years after the initial diagnosis, progre-
ssion to gliosarcoma occurred12. Nevertheless, the patient, 
an 8-year- old child, had more than 10 years of total survi-
val. Possible causes of the sarcomatous transformation may 
include radiotherapy and a phenotypic change of the tumor 
cells. Nevertheless, cases of extreme success are tempered 
by other reports; recurrence just one month after apparent 
total removal in a child has been reported11; in a series of 
seven patients, the lesion was described as having a highly 
malignant behavior and all were dead within 14 months 
despite aggressive treatment18; three out of ten patients 
died within 3 days of surgery30.
 A positive relationship has been shown between the 
length of survival of patients with glioblastomas and the 
presence of the giant cell variety6. Adding two recent clini-
cal series of patients harboring glioblastomas that survived 
for more than five years constituting as a whole 12 cases, 
one third (n=4) had giant cell glioblastoma13,47. Infiltration 
of the tumor by leukocytes has been regarded as a good 
prognostic factor in view of the enhanced immune res-
ponse of the organism that it may represent37,44; giant cells 
in this respect may function as magnifiers of the antigenic 
stimulus37. The presence of a fibrous stroma in giant cell 
glioblastoma may contribute to a precise delimitation of the 
tumor thereby facilitating radical surgical excision, a factor 
that may have some association with prolonged survival44. 
Alpha I antitrypsin detected with relatively high frequency 
in the giant cells may explain the bizarre size and pericellu-
lar reticulin fiber formation21.
 In giant cell glioblastoma gene p53 (syn. TP53) has 
a mutation in 75-89% of the cases34,39. Mutations have 
been studied in detail at the molecular level and reported: 
codon 285, G to A transition results in a glutamic acid to 
lysine substitution19; G>A transition at nucleotide 524, 
substitution of arginine by histidine at position 175 of the 
p53 protein44. The p53 gene is located on chromosome 17 
and is regarded a guardian of the genome; p53 protein is 
involved in cell cycle arrest and apoptosis when DNA 
is damaged28. Mutant p53 proteins are stable and can be 
detected by immunohistochemistry. These techniques dis-
close positivity for p53 protein in giant cell glioblastoma. 
Although the gene may be mutated and staining for the pro-
tein absent, and the protein may be found without a mutated 
gene, nuclear immunoreactivity for p53 protein is associa-
ted with an increased frequency of p53 gene mutation31. 
Approximately 30% frequency of PTEN (phosphatase 
and tensin homologue) gene mutations is recorded in giant 
cell glioblastoma40. The PTEN gene is located on chromo-
some 10 and it is related to cell cycle arrest, apoptosis and 
inhibition of cell motility; mutation allows cell division28. 
Strong survivin immunoreactivity has been shown for 
giant cell glioblastoma. The staining is only cytoplasmic. 
Survivin functions as an inhibitor of apoptosis protein. A 
trend exists towards survivin expression and higher grade 
of astrocytic tumors. However, this does not necessarily 
imply rapid division and poor prognosis since the marker is 
overexpressed in meningiomas and benign peripheral nerve 
sheath tumors45. A chromosomal abnormality consisting of 
loss of 17p, 1p and 19q has been described for giant cell 
glioblastoma; the combination of 1p and 19q deletions has 
been associated with a better prognosis4. Loss of 10p15 
in a subpopulation of tumor cells has been described44. 
Epidermal growth factor receptor (EGFR) gene amplifica-
tion, a genetic alteration with growth promoting potential, 
is not significant, and does not seem to play a role in the 
evolution of the tumor34,39. Similar considerations apply to 
genes CDK4-MDM240,44, n-myc5, c-myc5 and gli5. There is 
a relative absence of CDKN2A deletion, a genetic altera-
tion with growth promoting potential34. Defects of mitotic 
spindle checkpoint gene hBUB1 do not seem to be impli-
cated in giant cell glioblastoma as a cause of chromosomal 
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instability leading to aneuploidy. Mitotic checkpoint has 
to do with a delay in anaphase if spindle damage is pre-
sent in order to increase the probability of delivering an 
euploid genome to the daughter cells42. Immunoreactivity 
for neurotrophin Trk A and Trk B receptors is low in giant 
cell glioblastoma. Neurotrophin Trk A and Trk B receptors 
have been implied in tumor pathogenesis in an early stage. 
They respond to signals that elicit glial proliferation and 
are regarded as a factor of progression towards malignancy 
in low grade lesions where high levels of immunoreacti-
vity are present50. Overall, in what genomic aberrations 
are concerned, these have been classified as scarce when 
compared to the number usually present in the “common” 
glioblastoma, and some changes associated with a dismal 
prognosis (e.g. EGFR gene amplification, CDKN2A homo-
zygous deletion) are not found44.
 A somewhat elevated proliferation index of 25% (Ki-67 
nuclear antigen labeling index identified through MIB-1 
antibody) has been implicated as a factor responsible for 
the very early relapse of the tumor (expected figure for the 
“common” glioblastoma would be 15-20%, for cases of 
long survival <18%, for cases with poor prognosis >36%); 
microscopic tumor rests not visible in post-operative MR 
images were also considered of significance11. Giant cells 
synthesize DNA and the progression might be related to 
mutated tumor suppressor gene p5322. Markers of prolife-
rative potential such as proliferating cell nuclear antigen 
(PCNA) and Ki-67 can be strongly positive in the nuclei 
of multinucleated giant cells, especially in adult cases21. 
However, this should be interpreted in the context of the 
global behavior of the cell. Prognosis has been said to be 
determined by the biological behavior of mononucleated 
giant cells and small cells18. Multinucleated giant cells 
do not result from either cell fusion or cell degeneration. 
They seem to be cells that remain in mitosis between meta-
phase and telophase; the nuclei undergo division but the 
cytoplasm doesn’t. Multinucleated giant cells do not seem 
to have proliferative activity. Mononucleated cells on the 
contrary have this capacity and, if present in a significant 
proportion, may imply a worse prognosis29. Aurora-B is 
a kinase that functions in early and late mitotic events, 
chromosome segregation / condensation and cytokinesis. 
Aurora-B dysfunction has been shown in multinucleated 
giant tumor cells. This will cause aberrations in cytoplas-
mic cleavage without affecting nuclear division15. 
 Clinically and genetically giant cell glioblastoma has 
been placed in an intermediate position between the de 
novo “common” glioblastoma (primary type) and the 
“common” glioblastoma deriving from a precursor lesion 
(secondary type)25. Giant cell glioblastoma shares with 
secondary “common” glioblastoma p53 mutations in more 
than 70% of the cases and younger patient age at presenta-
tion; features shared with primary “common” glioblastoma 
are 30% frequency of PTEN mutations, short clinical his-
tory and absence of less malignant precursor lesion40. Ove-
rall, analyses of survival in large series seem to agree that 
the prognosis is somewhat better than that of “common” 
glioblastoma, e.g., 38 cases - 27.4 months average post-
operative survival35 24 cases - 57 weeks mean survival 
time37.
Conclusion
 Giant cell glioblastoma has a more benign entourage 
than “common” glioblastoma. Nevertheless, the individual 
patient variables and the biological features of the tumor, 
despite the giant cell morphology, should be well taken into 
account since an ominous course is also a possibility.
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